Atopic dermatitis, Bronchial asthma, Chronic urticaria, Eosinophilic chronic rhinosinusitis
Conditions
Interventions
None listed
Sponsors
JMDC Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: In this study, we will use the JMDC database. Patients diagnosed with atopic dermatitis (AD), bronchial asthma (BA), chronic urticaria (CU), or eosinophilic chronic rhinosinusitis (ECRS) after April 2018 were included. This cutoff date was chosen based on the most recent approval date among the exposure drugs (mepolizumab, benralizumab, dupilumab, and omalizumab). The definition for AD and BA required at least two diagnoses with an interval of 1-12 months, along with related medication, based on a previous validation study. For CU and ECRS, at least two recorded diagnoses with an interval of 1-12 months were required. The first diagnosis was defined as the index date (day 0). After that, patients were required to have continuous enrollment for >=365 days, no history of the exposure drugs, be aged >=18 years, and have at least one visit after day 0. For each outcome, patients with a pre-existing diagnosis of the relevant condition were excluded from the analysis.
Exclusion criteria
Exclusion criteria: Not applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The composite outcome of the following autoimmune diseases: Rheumatoid arthritis, systemic erythematosus, Sjogren's syndrome, dermatomyositis/polymyositis, mixed connective tissue disease, systemic sclerosis, polymyalgia rheumatica, ANCA-associated vasculitis, large vessel vasculitis, polyarteritis nodosa, psoriasis | — |
Secondary
| Measure | Time frame |
|---|---|
| The components of the primary outcome | — |
Countries
Japan
Contacts
Public ContactShoichiro Inokuchi
JMDC Inc. Real World Evidence Division, Pharmaceutical Business Unit
Outcome results
None listed